Navigation Links
Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair

Study Showing Results of Tengion Neo-Bladder Augment(TM) to be Featured in

July Issue of the Journal of Urology

EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced today that the results of a preclinical research study conducted with its Neo-Bladder Augment(R) will be featured in the July issue of the Journal of Urology, Vol. 180. The paper, "Early Cellular and Stromal Responses in Regeneration Versus Repair of a Mammalian Bladder Using Autologous Cell and Biodegradable Scaffold Technologies," was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., Belinda J. Wagner, Ph.D. and Timothy A. Bertram, D.V.M., Ph.D.

Key findings of the preclinical trial -- in which either a Tengion Neo-Bladder Augment or a biodegradable mesh scaffold alone was surgically implanted following partial, trigone-sparing cystectomy and both groups were evaluated clinically at one, three, six and nine months -- show that the Tengion Neo-Bladder Augment restored baseline urodynamics as early as six months after implantation and led to a structurally and functionally complete regenerated bladder wall as early as nine months. In contrast, scaffold implants alone failed to return to urodynamic baseline by the study termination and failed to regenerate a complete bladder wall.

"We continue to see great promise in our neo-bladder research programs and these latest data underscore the potential of Tengion's Autologous Organ Regeneration Platform(TM) to provide a neo-organ that allows the body to regenerate a functional organ," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion. "We are looking forward to formally sharing these findings with our peers and continuing to develop our Neo-Bladder Augment and the Tengion Neo-Bladder Replacement(R) to meet the critical patient needs that exist today."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at:

SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
6. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
7. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
8. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
9. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
10. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
Breaking Medicine News(10 mins):